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This retrospective multicenter study reviews the role of acute 
percutaneous transluminal coronary angioplasty in the treatment 
of cardiogenic shock complicating acute myocardial infarction to 
determine whether early reperfusion affects in-hospital and long-
term survival. From 1982 to 1985, 69 patients were treated with 
emergency angioplasty to attempt reperfusion of the infarct-
related artery. Balloon angioplasty was unsuccessful in 20 patients 
(group 1) and successful in 49 patients (group 2). 
Initial clinical and angiographic findings in the groups with 
unsuccessful and successful angioplasty were similar with respect 
to age (60.5 ± 2.3 versus 57 ± 1.8 years), infarct location (65% 
versus 65% anterior) and gender (65% versus 67% male). Hemo-
dynamic variables in the two groups, including systolic blood 
pressure (68 ± 4.3 versus 73 ± 1.6 mm Hg), left ventricular 
end-diastolic pressure (24.4 ± 2.4 versus 27 ± 1.0 mm Hg) and 
initial ejection fraction (28.5 ± 4% versus 32 ± 2%), were also 
similar. Twenty-nine patients received thrombolytic therapy with 
Cardiogenic shock develops in 5% to 10% of patients hospi-
talized with acute myocardial infarction (1,2). Despite dra-
matic improvements in acute coronary care, the 90% mor-
tality rate associated with cardiogenic shock remains 
essentially unchanged (3,4). Pathologic studies (5.6) demon-
strate extensive myocardial necrosis associated with throm-
botic occlusion of coronary arteries. Decreased myocardial 
perfusion results in progressive myocardial necrosis which 
perpetuates the vicious cycle of the shock state (7.8). De-
Wood et al. (9) demonstrated that rapid surgical revascular-
ization of the infarct-related artery resulted in a dramatic 
survival benefit in selected patients. Data from thrombolytic 
trials with respect to outcome in cardiogenic shock are 
limited. Percutaneous transluminal coronary angioplasty is 
an effective method of establishing coronary artery patency 
and can be more rapidly applied than can surgical revascu-
larization. A few series have reported (10-13) preliminary 
data on a survival advantage in patients with cardiogenic 
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streptokinase; the overall rate of reperfusion was 34%. Group 1 
patients had a short-term survival rate of 20%, compared with 
69% in group 2 patients (p < 0.0005). 
Thirty-eight patients survived the hospital period and were 
followed up for 24 to 54 months (mean 32.5 ± 2.4). Five patients 
(all in group 2) died during follow-up. The long-term incidence 
rate of congestive heart failure was 19%, arrhythmia 21 %, need 
for repeat angioplasty 17 % and coronary artery bypass grafting 
26%. Twenty-four month survival was significantly better in 
group 2 patients (54%) versus group 1 patients (11 %, p = 0.003). 
It is concluded that emergency coronary angioplasty improves 
initial and long-term survival in cardiogenic shock complicating 
myocardial infarction with survival contingent on establishing 
reperfusion. Patients who survive cardiogenic shock return to 
normal activity with a low incidence of recurrent cardiac compli-
cations. 
(J Am Coll CardioI1991;17:599-603) 
shock complicating acute myocardial infarction who un-
dergo successful angioplasty of the infarct-related artery. 
We (12) previously reviewed the results of angioplasty in 24 
patients and demonstrated a survival advantage in those with 
successful reperfusion of the infarct-related artery. We have 
now expanded our study to determine which factors predict 
successful angioplasty. 
This study reviews our multicenter experience with an-
gioplasty therapy in patients with cardiogenic shock compli-
cating acute myocardial infarction. The objectives of this 
study were I) to determine whether emergency angioplasty 
in the setting of acute myocardial infarction complicated by 
cardiogenic shock improves initial and long-term survival; 2) 
to delineate those factors that favorably or adversely affect 
survival; and 3) to determine the incidence of recurrent 
cardiac events and overall functional status in these patients 
after hospital discharge. 
Methods 
Study patients. Medical centers that published prelimi-
nary data in 1985 reviewing experience with cardiogenic 
shock complicating acute myocardial infarction were con-
tacted in November 1986. Participating institutions included 
the University of Michigan Medical Center, Ann Arbor, 
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Michigan; Mercy Medical Center, Des Moines. Iowa; Good 
Samaritan Hospital, Phoenix, Arizona; and Klinikum der 
Johannes Gutenberg-Universitat, MaiOl, Federal Republic 
of Germany. Data were collected on experience with coro-
nary angioplasty therapy of cardiogenic shock from January 
1982 to July 1985. 
Myocardial infarction was defined as 1) chest pain con-
sistent with myocardial ischemia; 2) ST segment elevation of 
at least 1 mm in electrocardiographic (ECG) limb leads or at 
least 2 mm in precordial leads; and 3) serum creatine kinase 
(CK) MB isoenzyme elevation. 
Cardiogenic shock was defined as 1) a systolic blood 
pressure <80 mm Hg without inotropic or intraaortic balloon 
pump support; 2) a systolic blood pressure <90 mm Hg with 
inotropic or intraaortic balloon pump support; 3) evidence of 
adequate volume expansion demonstrated by a pulmonary 
capillary wedge pressure> 12 mm Hg or a left ventricular 
end-diastolic pressure> 18 mm Hg. 
The final study group comprised 69 patients. All patients 
underwent emergency coronary angioplasty. Twenty pa-
tients (group 1) had unsuccessful reperfusion with balloon 
angioplasty; 49 patients (group 2) had successful reperfusion 
of the infarct-related artery. Patients were treated with 
sympathomimetic, vasodilator, cardiac glycoside and antiar-
rhythmic drugs and intraaortic balloon counterpulsation at 
the discretion of the staff cardiologist. 
Coronary angioplasty. Angioplasty was performed with 
standard angioplasty guiding catheters and steerable balloon 
systems. After initial coronary angiograms were obtained, 
attempts were made to pass the balloon catheter system 
across the culprit lesion. When successful, the balloon 
catheter was serially inflated until the angioplasty result was 
deemed adequate by an interventional cardiologist. Success-
ful angioplasty was defined as a reduction in luminal narrow-
ing by >20% to a residual narrowing of <50% of the 
coronary luminal diameter. Angioplasty of only the infarct-
related artery was attempted in each patient. The decision to 
perform coronary angioplasty was made by the interven-
tional cardiologist based on the anatomic characteristics of 
the coronary arteriogram. 
Clinical follow-up. All surviving patients were followed 
up clinically after hospital discharge for a mean of 32.5 ± 2.4 
months (range 24 to 54). A study physician or nurse con-
tacted all patients by telephone; if the patient could not be 
contacted directly, his or her personal physician was inter-
viewed or the medical chart was reviewed. 
Statistical analysis. All numerical results are expressed as 
mean values ± SEM. Tests for differences between the 
means were performed with two-tailed student t tests for 
analytical data. Discrete variables were analyzed with the 
chi-square test or Fisher exact test where appropriate. A p 
value < 0.05 was considered statistically significant. Cumu-
lative survival was calculated by the life-table method. 
Differences between survival curves were analyzed by the 
log-rank method. 
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Table 1. Clinical Data in 69 Patients With Postinfarction 
Cardiogenic Shock 
Group 1 Group 2 
(n = 20) (n = 49) P Value 
Age (yr) (mean ± SEM) 60.5 ± 2.3 57 ± 1.8 NS 
Male (%) 65 67 NS 
Myocardial infarction 53 35 NS 
(previous) (%) 
Infarct location (%) 
Anterior 65 65 NS 
Inferior 30 31 NS 
Lateral 5 2 NS 
Intraaortic balloon 58 74 NS 
pump 
Laboratory 
CK (IU) 4.250 ± 1.795 5.099 ± 924 NS 
Time to peak CK (h) 14 ± 4 15 ± 10 NS 
Shock to reperfusion 4 5 NS 
Imedian time. h) 
CK = creatine kinase: Group I = unsuccessful reperfusion after angio-
plasty: Group 2 = successful reperfusion. 
Results 
Clinical data (Tables 1 and 2). There were no differences 
between patients in group 1 (unsuccessful angioplasty) and 
group 2 (successful angioplasty) with respect to age, gender 
or history of previous myocardial infarction (Table 1). Me-
dian symptom duration (the onset of chest pain to attempted 
reperfusion) was similar in group 1 and group 2 (4 versus 
5 h); 70% of group 2 patients had successful reperfusion 
within 12 h. Both groups had a high incidence of anterior 
myocardial infarction and an equal frequency of inferior 
infarction. Isolated lateral or posterior myocardial infarction 
occurred rarely. Peak serum CK MB isoenzyme activity was 
similar in both groups. Group 2 patients demonstrated a 
trend toward earlier peak CK MB activity (13 ± 7.4 versus 
15 ± 10 h; p = NS). Intraaortic balloon counterpulsation was 
used with equal frequency in both groups. 
Hemodynamic variables (Table 2) obtained during cardio-
genic shock were similar in the two groups. No statistically 
significant difference was found with respect to systolic 
blood pressure, left ventricular end-diastolic pressure, car-
Table 2. Hemodynamic Data in 69 Patients 
Systolic blood pressure 
(mm Hg) 
Left ventricular end-diastolic 
pressure (mm Hg) 
Cardiac index (liters/min 
per ml) 
Angiographic ejection fraction 
(acute) 
Group I 
(n = 20) 
68 ± 4.3 
24 ± 2.4 
1.8 ± 0.5 
28.5 ± 4 
Data are expressed as numerical value ± SEM. 
Group 2 
(n = 49) p Value 
73 ± 1.6 NS 
27 ± 1.0 NS 
2.2 ± 0.6 NS 
32 ± 2 NS 
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Figure 1. Plot of 7 day survival after angioplasty for patients with 
successful reperfusion (group 2: n = 49) and unsuccessful reperfu-
sion (group I: n = 20). 
diac index or initial ejection fraction determined at acute 
angiography. 
Adjunctive thrombolytic therapy. Twenty-nine patients (8 
in group 1 versus 21 in group 2, p = NS) received throm-
bolytic therapy with streptokinase at the time of angioplasty. 
Four patients received 1.5 million U of intravenous strep-
tokinase (3 patients in group 1. 1 patient in group 2): the 
remaining 25 patients received intracoronary streptokinase 
(30,000 to 250,000 U). The overall reperfusion rate with 
thrombolytic therapy was 34%. 
Survival (Fig. 1 and 2). In-hospital (7 day) survival was 
significantly better in group 2 patients than in group 1 
patients (69% versus 20%, p < 0.0005) (Fig. 1). A long-term 
survival advantage persisted in group 2 patients. Patients 
were followed up clinically for a mean of 32.5 ± 2.4 months. 
At the time of follow-up 55% of group 2 patients were alive 
compared with 20% of group 1 patients (p < 0.002) (Fig. 2). 
The rate of survival to 24 months was 54% for group 2 
patients versus 11% for group 1 patients (p = 0.003). 
Univariate analysis demonstrated that patients with success-
Figure 2. Plot of long-term survival after angioplasty for patients 
with successful reperfusion (group 2: n = 34) and unsuccessful 
reperfusion (group I: n = 4). 
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Table 3. Clinical Follow-Up of 38 Patients 
Cardiac symptoms ('7c) 
Congestive heart failure 
Arrhythmia 
INYHAI functional class 
I 
II 
III-IV 
Cardiac procedures ('7c1 
Hospitalizations 
Coronary artery bypass surgery 
Cardiac catheterization 
PTCA l'if) 
None 
Same vessel 
New vessel 
19 
21 
85 
9 
6 
I.2/patient 
26 
48 
83 
14 
3 
Mean time to follow-up 32.5 months (range 24 to 54). NYHA = New York 
Heart Association: PTCA = percutaneous transluminal coronary angioplasty. 
ful angioplasty (group 2) and improved survival had a strong 
trend toward a higher incidence of single vessel coronary 
disease. Group 1 patients had an 80% incidence rate of 
multivessel disease compared with a rate of only 53% in 
group 2 patients (p = 0.07), 
Clinical follow-up (Table 3). Patients surviving cardio-
genic shock had a low incidence of congestive heart failure 
(19%) requiring medical treatment and the majority of pa-
tients (94%) had New York Heart Association functional 
class I or II symptoms. Serious arrhythmias requiring treat-
ment occurred in 21 % of patients. During the clinical fol-
low-up period. 48% of patients underwent repeat catheter-
ization with 17% requiring repeat angioplasty; 26% of 
patients were referred for coronary artery bypass grafting. A 
full active life-style was reported by 77% of patients; 17% 
reported moderate limitation of activity, whereas 6% were 
severely limited by cardiac symptoms. 
Discussion 
Role of coronary angioplasty therapy in the management of 
cardiogenic shock. This question was evaluated in four cen-
ters experienced in interventional therapy of acute myocar-
dial infarction. Because of the grave prognosis associated 
with cardiogenic shock complicating acute myocardial in-
farction we did not believe that true informed consent for a 
randomized controlled trial was possible. In lieu of a con-
trolled trial we developed carefully defined rigorous hemo-
dynamic and myocardial infarction inclusion criteria for the 
registry and followed up patients longitudinally over time to 
determine both the short-term and long-term results of 
aggressive management of this patient group. Because this 
study is not a controlled trial, a certain unrecognized selec-
tion bias may have been introduced. Only those patients 
surviving to undergo cardiac catheterization with suitable 
coronary anatomy could undergo angioplasty. We (10) have 
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previously reported a mortality rate >80% for patients 
treated with conventional medical therapy during this same 
period. Therefore. in this specific patient group our current 
study suggests that angioplasty in the setting of acute myo-
cardial infarction complicated by cardiogenic shock yields a 
high rate of coronary artery recanalization and imparts a 
survival advantage in those patients with successful reper-
fusion of the infarct-related artery. The mortality rate in 
patients with unsuccessful angioplasty was 80%. a rate 
essentially identical to that in conventionally treated histor-
ical control patients. The mortality rate in those patients 
with successful reperfusion of the infarct-related artery was 
reduced to 31% (p = 0.0005). Further, a long-term survival 
benefit persisted in patients treated with a successful reper-
fusion strategy. 
Previous studies. The role of percutaneous trans luminal 
angioplasty in the treatment of cardiogenic shock complicat-
ing acute myocardial infarction has been reviewed by rela-
tively few investigators. O'Neill et al. (11), in a cohort of 27 
patients with cardiogenic shock complicating acute myocar-
dial infarction, reported an in-hospital mortality rate of 67%; 
this rate was dramatically reduced to 25% in patients treated 
with successful emergency angioplasty of the infarct-related 
artery. Brown et al. (12) in a preliminary report described 
similar results in a series of 28 patients; the mortality rate in 
their study was 82% on those without reperfusion of the 
infarct-related artery but only 42% in those with reperfusion. 
Other preliminary reports (13,14) described lowered mortal-
ity in patients with cardiogenic shock and acute myocardial 
infarction after successful reperfusion of the infarct artery. 
We (10) previously reported our 10 year experience of 
angioplasty therapy for cardiogenic shock and acute myo-
cardial infarction. The mortality rate in patients treated 
without reperfusion of the infarct artery was 80% as com-
pared with 23% in patients with successful reperfusion of the 
infarct -related artery. Recanalization of the infarct -related 
artery with angioplasty in patients with cardiogenic shock 
and acute myocardial infarction was achieved in 71 % of the 
patients in the present study. Other angioplasty series (lO-
IS) have reported similar reperfusion rates of 54% to 88% for 
patients with cardiogenic shock. 
Disappointing results with respect to survival in patients 
with multivessel disease have been previously reported (10). 
In our study, patients with multivessel disease had an overall 
mortality rate of 62%. Despite successful angioplasty 31 % of 
patients died; 66% of these patients who died had multives-
sel coronary artery disease and only 33% had single vessel 
disease. The majority of our patients underwent angioplasty 
within 4 h of symptom onset; improved survival was docu-
mented in patients undergoing angioplasty many hours after 
this critical period. Animal studies (16) have demonstrated a 
beneficial effect of late reperfusion on limitation of infarct 
expansion and aneurysm formation independent of myocar-
dial salvage. Force et al. (17) demonstrated that with late 
coronary reperfusion an acute reduction in diastolic and 
systolic infarct expansion occurs in the dog. Furthermore, 
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delayed reperfusion may improve the rate and extent of 
infarct healing. 
Role of thrombolytic therapy. The efficacy of throm-
bolytic therapy in the setting of cardiogenic shock compli-
cating acute myocardial infarction was disappointing in our 
study. Although thrombolytic therapy offers a rapid method 
of achieving reperfusion, the frequency of successful reca-
nalization by this method remains low. Mathey et al. (18) and 
Rentrop et al. (19) reported low rates of thrombolysis in 
shock patients treated with intracoronary streptokinase. 
Neither study demonstrated any survival benefit in patients 
treated with thrombolytic therapy alone. Further, the 
Gruppo Italiano per 10 Studio della Streptochinasi nell'In-
farto Miocardico (GISSl) study (20) reported a high mortal-
ity rate in patients with cardiogenic shock treated with 
intravenous streptokinase. 
Clinical implications. The role of thrombolytic therapy 
and the need for further angioplasty in the setting of acute 
myocardial infarction remains a highly controversial topic. 
Recent results from GISSI-II (unpublished observations), 
the European Cooperative trial (21), the Should We Inter-
vene Following Thrombolysis (SWIFT) trial (22) and the 
Thrombolysis in Myocardial Infarction (TIMI) II-A trial (23) 
have all strongly suggested that watchful waiting is the 
correct approach for the majority of patients suffering from a 
relatively uncomplicated acute myocardial infarction. The 
role of early intervention after thrombolysis in higher risk 
patients (patients> 75 years old, or patients with extensive 
myocardium at risk) is unknown. Further, the use of early 
aggressive coronary angioplasty without thrombolysis in 
uncomplicated myocardial infarction is currently being eval-
uated. It appears, however, that in the setting of acute 
myocardial infarction complicated by cardiogenic shock a 
survival advantage is conferred by direct angioplasty of the 
infarct-related artery and that watchful waiting after throm-
bolysis is not a viable option in this high risk setting. 
This clinical registry suggests that successful angioplasty 
may significantly improve the dismal initial and long-term 
survival of patients with acute myocardial infarction compli-
cated by cardiogenic shock. Long-term clinical follow-up 
demonstrates that survivors return to normal activity with a 
relatively low incidence of recurrent cardiac complications. 
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